Gamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression

Launched by BAYLOR COLLEGE OF MEDICINE · Jun 24, 2024

Keywords

ClinConnect Summary

This clinical trial is investigating how gamma oscillations in the brain can help predict whether ketamine therapy will be effective for people with treatment-resistant depression (TRD). Ketamine is a medication that may help relieve symptoms of depression, but not everyone responds to it. The researchers want to see if measuring brain activity during ketamine treatment can give clues about how well a patient will do over the next four weeks. This study is particularly important because it looks at how patients might respond in real-life situations, not just in a controlled setting.

To participate in the trial, individuals must be between 21 and 45 years old and have been diagnosed with major depressive disorder (MDD), particularly those who have not found relief from at least two different antidepressants. Participants will need to be stable on their medications for at least four weeks before joining and will undergo assessments to understand their condition better. Throughout the trial, those who qualify will receive ketamine treatment and participate in monitoring sessions to track their brain activity and symptoms. It's important to note that this study excludes individuals with certain medical or psychiatric conditions to ensure safety during the trial.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. General
• • The criteria for eligibility described here are intended to protect patient welfare where, for example, the administration of ketamine in the context of standardized research (i.e. pharmaco-EEG challenge) would be inadvisable or unsafe. An additional purpose is to decrease psychiatric co-morbidities that may affect the clinical phenomenology or treatment response and thus obscure findings. Further, by virtue of the eligibility criteria the investigators seek to limit variability due to demographic and other factors.
• 2. All subjects Inclusion Criteria:
• • Male or Female ages 21-45, inclusive.
• • Level of understanding sufficient to agree to all tests and examinations required by the protocol.
• • 3. TRD patients
• • Major depressive disorder (MDD) diagnosis confirmed by MINI, with major depressive episode of at least 4 weeks duration.
• • MADRS score of 27 or greater.
• • Meet criteria for treatment resistance, defined as 2+ unsuccessful trials of antidepressants at an adequate dose for at least 6 weeks.
• • On a stable dose of all psychotropic medications (including antidepressant, antipsychotic, lithium, hypnotic, etc) for a minimum of 4 weeks prior to the Screening period.
• • 4. MDD patients
• • MDD diagnosis confirmed by the Mini International Neuropsychiatric Interview (MINI), with major depressive episode of at least 4 weeks duration.
• • MADRS score of less than or equal to 12.
• • On a stable dose of all psychotropic medications (including antidepressant, antipsychotic, lithium, hypnotic, etc) for a minimum of 4 weeks prior to the Screening period.
• Exclusion Criteria:
• • History of MDD with psychotic features, bipolar disorder, schizophrenia spectrum and other psychotic disorders, currently exhibiting psychotic features, or a first-degree relative with a psychotic disorder.
• • Diagnosed with intellectual disability.
• • Current major medical problems that affect brain anatomy, neurochemistry, or function, e.g., liver insufficiency, kidney insufficiency, cardiovascular problems, (unstable Arrhythmias, Chronic Heart Failure, Myocardial Infarction (MI) cardiac pacemaker), systemic infections, cancer, active upper respiratory infections, respiratory depression and any brain disorder (seizure disorder, stroke, dementia, degenerative neurologic diseases), and head injury with loss of consciousness for any period of time.
• • Pregnancy or Breast-feeding. All female participants in reproductive age will undergo pregnancy tests. Female participants will be required to provide evidence of use of contraceptives during the course of the study.
• • Unable to understand the design and requirements of the study.
• • Unable to sign the informed consent for any reason.
• • Patients with a severe personality disorder, including risk for homicide or aggressive behavior, which in the opinion of the investigator has a major impact on the patients' current psychiatric status and would preclude safe study participation.
• • Patients at serious and imminent risk of suicide and not suitable for an outpatient study, in the judgment of the investigators.
• • Patients taking medications with known activity at the N-methyl-D-aspartate (NMDA) or α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPA) glutamate receptor \[eg, riluzole, amantadine, lamotrigine, memantine, topiramate, dextromethorphan, D-cycloserine\], or the mu-opioid receptor.
• • Previous exposure to ketamine or esketamine.
• • Patients starting hormonal treatment (e.g., estrogen) in the 3 months prior to screening.
• • Patients with no regular contact with at least one adult. Patients who are un-domiciled are excluded.
• • Body mass index (BMI) \>=40 kg/m2.
• • Active eating disorder or cognitive deficit affecting the regulation of food intake.
• • Current or recent course of electroconvulsive therapy (ECT) (past month).
• • History of deep brain stimulation (DBS), vagal nerve stimulation (VNS) implantation, or other form of psychosurgery
• • Recently started cognitive behavioral therapy (CBT) (past month).
• • Patients taking \>6mg/day lorazepam (benzodiazepine)-equivalents. Patients with lower and/or infrequent use of benzodiazepines will be required to discontinue their dose on the morning (noting that this is already per protocol at the partner ketamine clinic).
• • Patients taking prescription opioids. Over the counter pain medications are proscribed on infusion days.
• • Dietary supplements affecting central nervous system (CNS) function will be discontinued before the study start. This will include supplementation of glutamate, serotonin (e.g. 5-hydroxytryptophan(HTP), St. John's Wort), creatine, γ-Aminobutyric acid (GABA).
• • Patients habitually consuming legal cannabis products containing cannabidiol (CBD) or delta-8-tetrahydrocannabinol (THC).
• • The participant has a known ketamine allergy or is taking any medication that may interact with ketamine.